scholarly journals Effects of Haloperidol and Atypical Neuroleptics on Psychomotor Performance and Driving Ability in Schizophrenic Patients

2003 ◽  
Vol 47 (4) ◽  
pp. 212-218 ◽  
Author(s):  
Sabine Kagerer ◽  
Catja Winter ◽  
Hans-Jürgen Möller ◽  
Michael Soyka
2001 ◽  
Vol 12 (1) ◽  
pp. 49-53 ◽  
Author(s):  
Michael Soyka ◽  
Sebastian Dittert ◽  
Martin Schäfer ◽  
Andreas Gartenmaier ◽  
Gerd Laux ◽  
...  

Abstract: Cognitive dysfunction has been recognized as an important clinical feature of schizophrenia. The possible pharmacological effect of neuroleptics on cognitive and psychomotor function including driving ability is crucial for rehabilitation of schizophrenic patients. Atypical neuroleptics such as risperidone have been shown to improve cognitive deficits in schizophrenics. We conducted a naturalistic nonrandomized clinical study to determine the effect of risperidone on psychomotor function compared to haloperidol in schizophrenic patients. In this study the psychomotor performance of 26 patients, who met the ICD-10 and DSM-IV criteria for schizophrenia, was assessed by means of ART-90, a computer-based Act & React Testsystem. 11 patients were on risperidone (mean dosage 4.0 mg) and 15 patients on haloperidol (mean dosage 10.5 mg). Patients were examined at discharge after psychopathological stabilization. In some relevant items the patients in the haloperidol group showed more impaired performance compared to the patients in the risperidone group. These preliminary data indicate a possible beneficial effect of risperidone compared to haloperidol on psychomotor performance and driving ability. Further randomized trials are necessary.


2001 ◽  
Vol 16 (6) ◽  
pp. 354-361 ◽  
Author(s):  
S. Moritz ◽  
B. Andresen ◽  
D. Jacobsen ◽  
K. Mersmann ◽  
U. Wilke ◽  
...  

SummaryThere is widespread evidence that schizophrenic symptomatology is best represented by three syndromes (positive, negative, disorganized). Both the disorganized and negative syndrome have been found to correlate with several neurocognitive dysfunctions. However, previous studies investigated samples predominantly treated with typical neuroleptics, which frequently induce parkinsonian symptoms that are hard to disentangle from primary negative symptoms and may have inflated correlations with neurocognition. A newly developed psychopathological instrument called the Positive and Negative and Disorganized Symptoms Scale (PANADSS) was evaluated in 60 schizophrenic patients. Forty-seven participants treated with atypical neuroleptics performed several neurocognitive tasks.A three-factor solution of schizophrenic symptomatology emerged. Negative symptomatology was associated with diminished creative verbal fluency and digit span backward, whereas disorganization was significantly correlated with impaired Stroop, WCST and Trail-Making Test B performance.Data suggest that disorganization is associated with tasks that demand executive functioning. Previous findings reporting correlations between negative symptomatology and neurocognition may have been confounded by the adverse consequences of typical neuroleptics.


1998 ◽  
Vol 31 (06) ◽  
pp. 232-235 ◽  
Author(s):  
M. Soyka ◽  
C. Aichmüller ◽  
U. Preuss ◽  
H.-J. Möller

2006 ◽  
Vol 187 (2) ◽  
pp. 222-228 ◽  
Author(s):  
Georg Juckel ◽  
Florian Schlagenhauf ◽  
Michael Koslowski ◽  
Dimitri Filonov ◽  
Torsten Wüstenberg ◽  
...  

1997 ◽  
Vol 170 (5) ◽  
pp. 422-425 ◽  
Author(s):  
M. Franz ◽  
Stefanie Lis ◽  
K. Plüddemann ◽  
B. Gallhofer

BackgroundThe effectiveness of anti-psychotic drugs against positive psychotic symptoms has been demonstrated in many studies, but their effects on quality of life have yet to be clarified. The impact of different neuroleptic therapies on the subjective quality of life of schizophrenic patients is evaluated in a cross-sectional open study.MethodDuring a four-month period a standardised quality of life interview for schizophrenic patients was applied on day 10 after admission; 33 patients on atypical neuroleptics (AAP) were compared with 31 matched patients on conventional neuroleptics (CAP).ResultsThe AAP group had significantly higher scores in general quality of life as well as in different life domains: physical well-being, social life and everyday life. In separate comparisons of the AAP group, patients on clozapine and risperidone were found to have a higher quality of life score than patients on CAP or zotepine.ConclusionsThe pharmacological profile of clozapine and risperidone may provide a basis for explaining the higher subjective quality of life found in this study. The lower quality of life of the CAP group may possibly be related to intrinsic effects of the conventional antipsychotics.


2012 ◽  
Vol 15 (2) ◽  
pp. 99
Author(s):  
Ji Hyun Han ◽  
Se Jin Park ◽  
Jong Il Lee ◽  
An Kee Chang ◽  
Shi Hyun Kang ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document